Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
Allison August, Husain Attarwala, Sunny Himansu, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2224-2233
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 180
A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development
Thaíse Yasmine Vasconcelos de Lima Cavalcanti, Mylena Ribeiro Pereira, Sérgio Oliveira de Paula, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 969-969
Open Access | Times Cited: 152
Emerging mRNA technologies: delivery strategies and biomedical applications
Yufen Xiao, Zhongmin Tang, Xiangang Huang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3828-3845
Closed Access | Times Cited: 150
Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 146
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Edo Kon, Nitay Ad‐El, Inbal Hazan‐Halevy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 739-754
Open Access | Times Cited: 136
Chikungunya fever
Koen Bartholomeeusen, Matthieu Daniel, Desiree A. LaBeaud, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 110
Circular RNA vaccine in disease prevention and treatment
Dun Niu, Yaran Wu, Jiqin Lian
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 99
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1192-1204
Closed Access | Times Cited: 77
Nanotechnology-based mRNA vaccines
Shuying Chen, Xiangang Huang, Yonger Xue, et al.
Nature Reviews Methods Primers (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 73
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 51
Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses
Longze Pan, Lijing Zhang, Wenjing Deng, et al.
Journal of Controlled Release (2023) Vol. 357, pp. 133-148
Closed Access | Times Cited: 46
The immunostimulatory nature of mRNA lipid nanoparticles
Preeti Sharma, Daniek Hoorn, Anjaiah Aitha, et al.
Advanced Drug Delivery Reviews (2024) Vol. 205, pp. 115175-115175
Open Access | Times Cited: 42
Frameworks for transformational breakthroughs in RNA-based medicines
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 26
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Norbert Pardi, Florian Krammer
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 23
A comprehensive comparison of DNA and RNA vaccines
Chunxi Wang, Fan Yuan
Advanced Drug Delivery Reviews (2024) Vol. 210, pp. 115340-115340
Closed Access | Times Cited: 20
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Julie Ostrowsky, Leah C. Katzelnick, Nigel Bourne, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 3
Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment
Aftab Ullah, Marina Khan, Yibang Zhang, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 25-52
Open Access | Times Cited: 2
A molecular understanding of alphavirus entry and antibody protection
Arthur S. Kim, Michael Diamond
Nature Reviews Microbiology (2022) Vol. 21, Iss. 6, pp. 396-407
Open Access | Times Cited: 42
Human Antibodies for Viral Infections
James E. Crowe
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 349-386
Closed Access | Times Cited: 39
Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein
Seymour de Picciotto, Nicholas DeVita, Chiaowen Joyce Hsiao, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 39
Ionizable Lipid Nanoparticles for mRNA Delivery
Xuefeng Tang, Ying Zhang, Xiaojun Han
Advanced NanoBiomed Research (2023) Vol. 3, Iss. 8
Open Access | Times Cited: 29
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Hanjin Seo, Leekang Jeon, Jaeyeong Kwon, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 13
Closed Access | Times Cited: 25
Nucleic acid drugs: recent progress and future perspectives
Xiaoyi Sun, Sarra Setrerrahmane, Chencheng Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d
Namit Chaudhary, Lisa N. Kasiewicz, Alexandra N. Newby, et al.
Nature Biomedical Engineering (2024)
Closed Access | Times Cited: 12
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Yingying Shi, Miaoyuan Shi, Yì Wáng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top